| Title |
SARS-CoV-2 infection, sex-related differences, and a possible personalized treatment approach with valproic acid: a review / |
| Authors |
Stakišaitis, Donatas ; Kapočius, Linas ; Valančiūtė, Angelija ; Balnytė, Ingrida ; Tamošuitis, Tomas ; Vaitkevičius, Arūnas ; Sužiedėlis, Kęstutis ; Urbonienė, Daiva ; Tatarūnas, Vacis ; Kilimaitė, Evelina ; Gečys, Dovydas ; Lesauskaitė, Vaiva |
| DOI |
10.3390/biomedicines10050962 |
| Full Text |
|
| Is Part of |
Biomedicines.. Basel : MDPI AG. 2022, vol. 10, iss. 5, p. [1-23].. eISSN 2227-9059 |
| Abstract [eng] |
Sex differences identified in the COVID-19 pandemic are necessary to study. It is essential to investigate the efficacy of the drugs in clinical trials for the treatment of COVID-19, and to analyse the sex-related beneficial and adverse effects. The histone deacetylase inhibitor valproic acid (VPA) is a potential drug that could be adapted to prevent the progression and complications of SARS-CoV-2 infection. VPA has a history of research in the treatment of various viral infections. This article reviews the preclinical data, showing that the pharmacological impact of VPA may apply to COVID-19 pathogenetic mechanisms. VPA inhibits SARS-CoV-2 virus entry, suppresses the pro-inflammatory immune cell and cytokine response to infection, and reduces inflammatory tissue and organ damage by mechanisms that may appear to be sex-related. The antithrombotic, antiplatelet, anti-inflammatory, immunomodulatory, glucose- and testosterone-lowering in blood serum effects of VPA suggest that the drug could be promising for therapy of COVID-19. Sex-related differences in the efficacy of VPA treatment may be significant in developing a personalised treatment strategy for COVID-19. |
| Published |
Basel : MDPI AG |
| Type |
Journal article |
| Language |
English |
| Publication date |
2022 |
| CC license |
|
